In a set of 317 primary breast cancers patients with known clinical outcome (STB data set), we evaluated E2F1 mRNA expression levels with respect to other proliferation markers, ER and ERBB2 status and clinical outcome. The gene discussed is ERBB2; the disease is breast carcinoma.